Literature DB >> 11602739

Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein.

L Deml1, A Bojak, S Steck, M Graf, J Wild, R Schirmbeck, H Wolf, R Wagner.   

Abstract

We have analyzed the influence of codon usage modifications on the expression levels and immunogenicity of DNA vaccines, encoding the human immunodeficiency virus type 1 (HIV-1) group-specific antigen (Gag). In the presence of Rev, an expression vector containing the wild-type (wt) gag gene flanked by essential cis-acting sites such as the 5'-untranslated region and 3'-Rev response element supported substantial Gag protein expression and secretion in human H1299 and monkey COS-7 cells. However, only weak Gag production was observed from the murine muscle cell line C2C12. In contrast, optimization of the Gag coding sequence to that of highly expressed mammalian genes (syngag) resulted in an obvious increase in the G+C content and a Rev-independent expression and secretion of Gag in all tested mammalian cell lines, including murine C2C12 muscle cells. Mice immunized intramuscularly with the syngag plasmid showed Th1-driven humoral and cellular responses that were substantially higher than those obtained after injection of the Rev-dependent wild-type (wt) gag vector system. In contrast, intradermal immunization of both wt gag and syngag vector systems with the particle gun induced a Th2-biased antibody response and no cytotoxic T lymphocytes. Deletion analysis demonstrated that the CpG motifs generated within syngag by codon optimization do not contribute significantly to the high immunogenicity of the syngag plasmid. Moreover, low doses of coadministered stimulatory phosphorothioate oligodeoxynucleotides (ODNs) had only a weak effect on antibody production, whereas at higher doses immunostimulatory and nonstimulatory ODNs showed a dose-dependent suppression of humoral responses. These results suggest that increased Gag expression, rather than modulation of CpG-driven vector immunity, is responsible for the enhanced immunogenicity of the syngag DNA vaccine.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602739      PMCID: PMC114679          DOI: 10.1128/JVI.75.22.10991-11001.2001

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

Review 1.  DNA vaccines: immunology, application, and optimization*.

Authors:  S Gurunathan; D M Klinman; R A Seder
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells.

Authors:  P D Bieniasz; B R Cullen
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Immunization against SIVmne in macaques using multigenic DNA vaccines.

Authors:  S P Mossman; C C Pierce; M N Robertson; A J Watson; D C Montefiori; M Rabin; L Kuller; J Thompson; J B Lynch; W R Morton; R E Benveniste; R Munn; S L Hu; P Greenberg; N L Haigwood
Journal:  J Med Primatol       Date:  1999 Aug-Oct       Impact factor: 0.667

4.  Development of autoreactive L3T4+ T cells from double-negative (L3T4-/Ly-2-) Thy-1+ spleen cells of normal mice.

Authors:  J Reimann; A Bellan; P Conradt
Journal:  Eur J Immunol       Date:  1988-07       Impact factor: 5.532

5.  Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization.

Authors:  D M Feltquate; S Heaney; R G Webster; H L Robinson
Journal:  J Immunol       Date:  1997-03-01       Impact factor: 5.422

6.  A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene.

Authors:  E Kotsopoulou; V N Kim; A J Kingsman; S M Kingsman; K A Mitrophanous
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

7.  Increased expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 gag gene.

Authors:  J zur Megede; M C Chen; B Doe; M Schaefer; C E Greer; M Selby; G R Otten; S W Barnett
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

8.  Concerted action of multiple cis-acting sequences is required for Rev dependence of late human immunodeficiency virus type 1 gene expression.

Authors:  M Graf; A Bojak; L Deml; K Bieler; H Wolf; R Wagner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

9.  A block to human immunodeficiency virus type 1 assembly in murine cells.

Authors:  R Mariani; G Rutter; M E Harris; T J Hope; H G Kräusslich; N R Landau
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

10.  Monoclonal antibodies directed against human immunodeficiency virus (HIV) gag proteins with specificity for conserved epitopes in HIV-1, HIV-2 and simian immunodeficiency virus.

Authors:  M Niedrig; J P Rabanus; J L'Age Stehr; H R Gelderblom; G Pauli
Journal:  J Gen Virol       Date:  1988-08       Impact factor: 3.891

View more
  76 in total

1.  Comparative analysis of immune responses induced by vaccination with SIV antigens by recombinant Ad5 vector or plasmid DNA in rhesus macaques.

Authors:  Lauren A Hirao; Ling Wu; Abhishek Satishchandran; Amir S Khan; Ruxandra Draghia-Akli; Adam C Finnefrock; Andrew J Bett; Michael R Betts; Danilo R Casimiro; Niranjan Y Sardesai; J Joseph Kim; John W Shiver; David B Weiner
Journal:  Mol Ther       Date:  2010-06-15       Impact factor: 11.454

2.  Optimization of codon usage enhances the immunogenicity of a DNA vaccine encoding mycobacterial antigen Ag85B.

Authors:  Hyun-Jeong Ko; Sung-Youl Ko; Yeon-Jeong Kim; Eun-Gae Lee; Sang-Nae Cho; Chang-Yuil Kang
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 3.  Expression library immunization: a road map for discovery of vaccines against infectious diseases.

Authors:  Adel M Talaat; Katherine Stemke-Hale
Journal:  Infect Immun       Date:  2005-11       Impact factor: 3.441

4.  Alphavirus replicon approach to promoterless analysis of IRES elements.

Authors:  K I Kamrud; M Custer; J M Dudek; G Owens; K D Alterson; J S Lee; J L Groebner; J F Smith
Journal:  Virology       Date:  2006-12-06       Impact factor: 3.616

5.  Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.

Authors:  Shixia Wang; Jessica Taaffe; Christopher Parker; Alicia Solórzano; Hong Cao; Adolfo García-Sastre; Shan Lu
Journal:  J Virol       Date:  2006-09-20       Impact factor: 5.103

Review 6.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

7.  Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.

Authors:  Jian Yan; Panyupa Pankhong; Thomas H Shin; Nyamekye Obeng-Adjei; Matthew P Morrow; Jewell N Walters; Amir S Khan; Niranjan Y Sardesai; David B Weiner
Journal:  Cancer Immunol Res       Date:  2013-07-17       Impact factor: 11.151

8.  Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques.

Authors:  Jian Yan; Kristina Harris; Amir S Khan; Ruxandra Draghia-Akli; Duane Sewell; David B Weiner
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

9.  Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

Authors:  Joseph F Bower; Xinzhen Yang; Joseph Sodroski; Ted M Ross
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Embedding permanent watermarks in synthetic genes.

Authors:  Michael Liss; Daniela Daubert; Kathrin Brunner; Kristina Kliche; Ulrich Hammes; Andreas Leiherer; Ralf Wagner
Journal:  PLoS One       Date:  2012-08-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.